Working… Menu

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04098796
Recruitment Status : Recruiting
First Posted : September 23, 2019
Last Update Posted : April 14, 2021
Information provided by (Responsible Party):
Jingdong Zhang, China Medical University, China

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2021